glp 1 non responders Mechanism by which excessive circulating levels of GLP-1 may lead to Why aren't I losing weight
Description
individual results will vary

The subsequent increase in cAMP leads to the activation of cAMP-regulated guanine nucleotide exchange factor 2 (cAMP-GEFII or Epac2) and protein kinase A (PKA)

This dual mechanism produces greater effects: clinical trials show tirzepatide produces approximately 2.0-2.3 percentage point reductions in HbA1c (versus 1.5-1.8 for semaglutide) and 15-22% weight loss (versus 10-15% for semaglutide)

aHR, adjusted hazard ratio

Recent Developments/ Strategic Initiatives 8.5.4

Silveira SQ, da Silva LM, de Campos Vieira Abib A, et al